Heathcliff Dorado García

Heathcliff Dorado García

Auto-generated profile, based on publicly available information

Heathcliff Dorado García

Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RKRichard P. Koche
Richard P. Koche
ERElias Rodriguez-Fos
Elias Rodriguez-Fos
KHKonstantin Helmsauer
Konstantin Helmsauer
MBMartin Burkert
Martin Burkert
IMIan C. MacArthur
Ian C. MacArthur
AHAnton G. Henssen
Anton G. Henssen

16 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKonstantin Helmsauer
Konstantin Helmsauer
M(Maria Stefanova (Valieva)
Maria Stefanova (Valieva)
SASalaheddine Ali
Salaheddine Ali
RGRocío Chamorro González
Rocío Chamorro González
RSRobert Schöpflin
Robert Schöpflin
RKRichard P. Koche
Richard P. Koche
MYCN amplification drives one in six cases of neuroblastoma. The supernumerary gene copies are commonly found on highly rearranged, extrachromosomal circular DNA (ecDNA). The exact amplicon structure has not been described thus far and the functional relevance of its rearrangements is unknown. Here, we analyze the MYCN amplicon structure using short-read and Nanopore sequencing and its chromatin landscape using ChIP-seq, ATAC-seq and Hi-C. This reveals two distinct classes of amplicons which explain the regulatory requirements for MYCN overexpression. The first class always co-amplifies a proximal enhancer driven by the noradrenergic core regulatory circuit (CRC). The second class of MYCN amplicons is characterized by high structural complexity, lacks key local enhancers, and instead contains distal chromosomal fragments harboring CRC-driven enhancers. Thus, ectopic enhancer hijacking can compensate for the loss of local gene regulatory elements and explains a large component of the structural diversity observed in MYCN amplification.

11 February 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
IRIsabelle Roeschert
Isabelle Roeschert
EPEvon Poon
Evon Poon
AHAnton G. Henssen
Anton G. Henssen
HGHeathcliff Dorado Garcia
Heathcliff Dorado Garcia
MGMarco Gatti
Marco Gatti
MEMartin Eilers
Martin Eilers

4 May 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RGRocío Chamorro González
Rocío Chamorro González
TCThomas Conrad
Thomas Conrad
MSMaja C. Stöber
Maja C. Stöber
RXRobin Xu
Robin Xu
MGMădălina Giurgiu
Mădălina Giurgiu
AHAnton G. Henssen
Anton G. Henssen
Extrachromosomal DNAs (ecDNAs) are common in cancer, but many questions about their origin, structural dynamics and impact on intratumor heterogeneity are still unresolved. Here we describe single-cell extrachromosomal circular DNA and transcriptome sequencing (scEC&T-seq), a method for parallel sequencing of circular DNAs and full-length mRNA from single cells. By applying scEC&T-seq to cancer cells, we describe intercellular differences in ecDNA content while investigating their structural heterogeneity and transcriptional impact. Oncogene-containing ecDNAs were clonally present in cancer cells and drove intercellular oncogene expression differences. In contrast, other small circular DNAs were exclusive to individual cells, indicating differences in their selection and propagation. Intercellular differences in ecDNA structure pointed to circular recombination as a mechanism of ecDNA evolution. These results demonstrate scEC&T-seq as an approach to systematically characterize both small and large circular DNA in cancer cells, which will facilitate the analysis of these DNA elements in cancer and beyond.

1 November 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
AHAnton G. Henssen
Anton G. Henssen
CRCasie Reed
Casie Reed
EJEileen Jiang
Eileen Jiang
HGHeathcliff Dorado Garcia
Heathcliff Dorado Garcia
JSJennifer von Stebut
Jennifer von Stebut
AKAlex Kentsis
Alex Kentsis
Despite intense efforts, the cure rates of childhood and adult solid tumors are not satisfactory. Resistance to intensive chemotherapy is common, and targets for molecular therapies are largely undefined. We have found that the majority of childhood solid tumors, including rhabdoid tumors, neuroblastoma, medulloblastoma, and Ewing sarcoma, express an active DNA transposase, PGBD5, that can promote site-specific genomic rearrangements in human cells. Using functional genetic approaches, we discovered that mouse and human cells deficient in nonhomologous end joining (NHEJ) DNA repair cannot tolerate the expression of PGBD5. In a chemical screen of DNA damage signaling inhibitors, we identified AZD6738 as a specific sensitizer of PGBD5-dependent DNA damage and apoptosis. We found that expression of PGBD5, but not its nuclease activity–deficient mutant, was sufficient to induce sensitivity to AZD6738. Depletion of endogenous PGBD5 conferred resistance to AZD6738 in human tumor cells. PGBD5-expressing tumor cells accumulated unrepaired DNA damage in response to AZD6738 treatment and underwent apoptosis in both dividing and G1-phase cells in the absence of immediate DNA replication stress. Accordingly, AZD6738 exhibited nanomolar potency against most neuroblastoma, medulloblastoma, Ewing sarcoma, and rhabdoid tumor cells tested while sparing nontransformed human and mouse embryonic fibroblasts in vitro. Finally, treatment with AZD6738 induced apoptosis and regression of human neuroblastoma and medulloblastoma tumors engrafted in immunodeficient mice in vivo. This effect was potentiated by combined treatment with cisplatin, including substantial antitumor activity against patient-derived primary neuroblastoma xenografts. These findings delineate a therapeutically actionable synthetic dependency induced in PGBD5-expressing solid tumors.

29 December 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
FPFabian F. Pusch
Fabian F. Pusch
HGHeathcliff Dorado García
Heathcliff Dorado García
RXRobin Xu
Robin Xu
DGDennis Gürgen
Dennis Gürgen
YBYi Bei
Yi Bei
AHAnton G. Henssen
Anton G. Henssen
The small-molecule inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), elimusertib, is currently being tested clinically in various cancer entities in adults and children. Its preclinical antitumor activity in pediatric malignancies, however, is largely unknown. We here assessed the preclinical activity of elimusertib in 38 cell lines and 32 patient-derived xenograft (PDX) models derived from common pediatric solid tumor entities. Detailed in vitro and in vivo molecular characterization of the treated models enabled the evaluation of response biomarkers. Pronounced objective response rates were observed for elimusertib monotherapy in PDX, when treated with a regimen currently used in clinical trials. Strikingly, elimusertib showed stronger antitumor effects than some standard-of-care chemotherapies, particularly in alveolar rhabdomysarcoma PDX. Thus, elimusertib has strong preclinical antitumor activity in pediatric solid tumor models, which may translate to clinically meaningful responses in patients.